Arcutis Biotherapeutics (NASDAQ: ARQT) has been garnering attention from analysts in recent months, with a noticeable uptick in price targets.
In the last 30 days alone, there have been 9 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings for ARQT, with an average price target of $10.25. The consensus rating for Arcutis Biotherapeutics is a Moderate Buy, based on 3 buy ratings, 2 hold ratings, and 0 sell ratings.
Analysts have been making adjustments to their ratings and price targets for ARQT as of late. Notably, analysts from Needham and Mizuho have raised their Buy ratings to $16.00 from $8.00, indicating a positive outlook on the company’s future performance. The average price target for Arcutis Biotherapeutics stands at $12.00, with a high estimate of $16.00 and a low estimate of $8.00.
Overall, analysts’ sentiments towards Arcutis Biotherapeutics point to a positive trajectory, with an increase in price targets and Buy ratings. This suggests a growing confidence in the company’s potential growth and market performance.
As of February 28, 2024, Arcutis Biotherapeutics is poised for a promising future according to analyst evaluations.
ARQT Stock Shows Strong Performance on February 28, 2024: Investors Should Monitor for Potential Growth Opportunities
On February 28, 2024, ARQT stock showed strong performance, with the price of shares increasing by $0.94, or 9.70%, since the market closed. Despite the strong performance during regular trading hours, ARQT stock dropped by $0.03 in after-hours trading. Overall, ARQT stock has shown positive momentum on February 28, 2024, with a significant increase in price during regular trading hours. Investors should continue to monitor the stock’s performance and consider factors such as market trends and company news when making investment decisions.
ARQT Stock Performance Analysis: Revenue Soars 1517.09% Year-Over-Year
On February 28, 2024, ARQT stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $59.61 million, which represents a significant increase of 1517.09% compared to the previous year. However, the total revenue for the fourth quarter of the same year was $13.53 million, showing a decrease of 64.51% from the previous quarter. In terms of net income, ARQT reported a net loss of $262.14 million for the past year, which was an improvement of 15.83% compared to the previous year. The net loss for the fourth quarter was $66.28 million, showing no change from the previous quarter. Earnings per share (EPS) for ARQT stock were reported at -$3.78 for the past year, representing an increase of 33.17% compared to the previous year. The EPS for the fourth quarter was -$0.72, showing a slight increase of 1.27% from the previous quarter. Overall, the financial performance of ARQT stock on February 28, 2024, reflected a mixed picture. Investors may want to closely monitor the company’s financial performance and future outlook to make informed decisions regarding ARQT stock.
